시장보고서
상품코드
1472608

POC(Point of Care)에서의 분자진단 시장 : 용도별, 기술별, 장소별, 제품별, 국가별 예측 - 이그제큐티브 및 컨설턴트 가이드 첨부(2024-2028년)

Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Analysis 2024 - 2028

발행일: | 리서치사: Howe Sound Research | 페이지 정보: 영문 486 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 POC(Point of Care)에서의 분자진단 시장에 대해 조사했으며, 시장의 개요와 용도별, 기술별, 장소별, 제품별, 국가별 동향 및 시장에 참여하는 기업의 개요 등을 제공하고 있습니다.

목차

제1장 시장 가이드

제2장 서론과 시장의 정의

  • POC(Point of Care)에서의 분자진단이란 무엇인가?
  • 진단 혁명
  • 시장의 정의
  • 조사 방법
  • 시점 : 헬스케어와 IVD 업계

제3장 계측, 자동화, 진단의 동향

  • 계측과 자동화

제4장 업계의 개요

  • 시장 참여 조직
    • 학술연구기관
    • 진단 시험 개발자
    • 계측 공급업체
    • 약품·시약 제조업체
    • 병리 공급업체
    • 독립계 임상 검사실
    • 국립/지역 연구소
    • 병원 검사실
    • 임상 검사실
    • 감사 기관
    • 인증 기관
  • 임상 검사 시장의 부문
  • 업계 구조

제5장 주요 기업의 개요

  • Abbott Laboratories
  • Abionic
  • Accelerate Diagnostics
  • Access Bio
  • Ador Diagnostics
  • ADT Biotech
  • Akonni Biosystems
  • Alveo Technologies
  • Anitoa
  • Applied BioCode
  • Aureum Diagnostics
  • Aus Diagnostics
  • Autonomous Medical Devices
  • Baebies
  • Beckman Coulter Diagnostics(Danaher)
  • Becton, Dickinson and Company
  • Binx Health
  • Biocartis
  • BioFire Diagnostics(bioMerieux)
  • bioMerieux Diagnostics
  • Bio-Rad Laboratories, Inc
  • Bosch Healthcare Solutions GmbH
  • Cepheid(Danaher)
  • Credo Diagnostics Biomedical
  • Cue Health
  • Curetis(OpGen)
  • Detect
  • Diagenode Diagnostics(Hologic)
  • Diasorin S.p.A.
  • DNAe
  • Domus Diagnostics
  • Enzo Biochem
  • Eurofins Scientific
  • Fluxergy
  • Fusion Genomics.
  • Genedrive
  • Genetic Signatures
  • GenMark Dx(Roche)
  • Genomadix
  • Getlabs
  • Global Access Diagnostics
  • Grip Molecular Technologies
  • Hologic
  • Immunexpress
  • Inflammatix
  • Invetech
  • Iollo
  • J&J Innovative Medicine
  • Karius
  • Lucira Health(Pfizer)
  • LumiraDx
  • Maxim Biomedical
  • Meep
  • Meridian Bioscience
  • Millipore Sigma
  • Molbio Diagnostics
  • NanoDx
  • Nanomix
  • Novacyt
  • Novel Microdevices
  • Novus Diagnostics
  • Nuclein
  • OnsiteGene
  • Operon
  • OraSure Technologies
  • Oxford Nanopore Technologies
  • Panagene
  • Prenetics
  • Primerdesign(Novacyt)
  • Prominex
  • Proof Diagnostics
  • Qiagen
  • QuantuMDx
  • QuidelOrtho
  • R-Biopharm AG
  • Response Biomedical
  • Revvity
  • Roche Diagnostics
  • Salignostics
  • SD Biosensor
  • Seegene
  • Siemens Healthineers
  • Sona Nanotech
  • SpeeDx
  • T2 Biosystems
  • Talis Biomedical
  • Thermo Fisher Scientific
  • Uniogen
  • Veramarx
  • Veredus Laboratories
  • XCR Diagnostics
  • Zhejiang Orient Gene Biotech

제6장 시장 동향

  • 성장 촉진요인
  • 성장 억제요인

제7장 분자진단 - 감염증의 최근 동향

제8장 세계의 POC(Point of Care)에서의 분자진단 시장

  • 국가별 세계 시장 개요
  • 용도별 세계 시장 - 개요
  • 기술별 세계 시장 - 개요
  • 지역별 세계 시장 - 개요
  • 제품별 세계 시장 - 개요

제9장 세계의 POC(Point of Care)에서의 분자진단 시장 - 용도별

  • 호흡기 감염증
  • 소화기 감염증
  • 성감염증
  • 기타

제10장 세계의 POC(Point of Care)에서의 분자진단 시장 - 기술별

  • PCR
  • NGS/프로브
  • 기타

제11장 세계의 POC(Point of Care)에서의 분자진단 시장 - 장소별

  • 병원
  • 클리닉, 진료소
  • 고령자 시설
  • 기타

제12장 세계의 POC(Point of Care)에서의 분자진단 시장 - 제품별

  • 기기
  • 카트리지
  • 기타

제13장 부록

KSA 24.05.13

OVERVIEW:

Can a rapidly growing market expand even faster? Find out all about it in this comprehensive report on Molecular Diagnostics at the Point of Care.

Point of Care testing is proving itself in the market. Players are reporting surprising growth. Lowering costs, improving outcomes and even helping in the battle against Anti Microbial Resistance. Learn about this market including the issues and outlooks. It could possibly displace most frontline test protocols AND save money at the same time. The report forecasts the market size out for five years.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

1. Market Guides

  • 1.1. Strategic Situation Analysis
  • 1.2. Guide for Executives, Marketing and Business Development Staff
  • 1.3. Guide for Management Consultants and Investment Advisors

2. Introduction and Market Definition

  • 2.1. What are Molecular Diagnostics at the Point of Care?
  • 2.2. The Diagnostics Revolution
  • 2.3. Market Definition
    • 2.3.1. Revenues
  • 2.4. Methodology
    • 2.4.1. Methodology
    • 2.4.2. Sources
    • 2.4.3. Authors
  • 2.5. Perspective: Healthcare and the IVD Industry
    • 2.5.1. Global Healthcare Spending
    • 2.5.2. Spending on Diagnostics
    • 2.5.3. Important Role of Insurance for Diagnostics

3. Instrumentation, Automation and Diagnostic Trends

  • 3.1. Instrumentation and Automation
    • 3.1.1. Traditional Automation and Centralization
    • 3.1.2. The New Automation, Decentralization and Point Of Care
    • 3.1.3. Instruments Key to Market Share
    • 3.1.4. Bioinformatics Plays a Role
    • 3.1.5. PCR Takes Command
    • 3.1.6. Next Generation Sequencing Fuels a Revolution
    • 3.1.7. NGS Impact on Pricing
    • 3.1.8. Whole Genome Sequencing, A Brave New World
    • 3.1.9. Companion Diagnostics Blurs Diagnosis and Treatment

4. Industry Overview

  • 4.1. Players in a Dynamic Market
    • 4.1.1. Academic Research Lab
    • 4.1.2. Diagnostic Test Developer
    • 4.1.3. Instrumentation Supplier
    • 4.1.4. Chemical/Reagent Supplier
    • 4.1.5. Pathology Supplier
    • 4.1.6. Independent Clinical Laboratory
    • 4.1.7. Public National/regional Laboratory
    • 4.1.8. Hospital Laboratory
    • 4.1.9. Physicians Office Lab (POLS)
    • 4.1.10. Audit Body
    • 4.1.11. Certification Body
  • 4.2. The Clinical Laboratory Market Segments
    • 4.2.1. Traditional Market Segmentation
    • 4.2.2. Laboratory Focus and Segmentation
  • 4.3. Industry Structure
    • 4.3.1. Hospital Testing Share
    • 4.3.2. Economies of Scale
      • 4.3.2.1. Hospital vs. Central Lab
    • 4.3.3. Physician Office Lab's
    • 4.3.4. Physician's and POCT

5. Profiles of Key MDx Companies

  • 5.1. Abbott Laboratories
  • 5.2. Abionic
  • 5.3. Accelerate Diagnostics
  • 5.4. Access Bio
  • 5.5. Ador Diagnostics
  • 5.6. ADT Biotech
  • 5.7. Akonni Biosystems
  • 5.8. Alveo Technologies
  • 5.9. Anitoa
  • 5.10. Applied BioCode
  • 5.11. Aureum Diagnostics
  • 5.12. Aus Diagnostics
  • 5.13. Autonomous Medical Devices
  • 5.14. Baebies
  • 5.15. Beckman Coulter Diagnostics (Danaher)
  • 5.16. Becton, Dickinson and Company
  • 5.17. Binx Health
  • 5.18. Biocartis
  • 5.19. BioFire Diagnostics (bioMerieux)
  • 5.20. bioMerieux Diagnostics
  • 5.21. Bio-Rad Laboratories, Inc
  • 5.22. Bosch Healthcare Solutions GmbH
  • 5.23. Cepheid (Danaher)
  • 5.24. Credo Diagnostics Biomedical
  • 5.25. Cue Health
  • 5.26. Curetis (OpGen)
  • 5.27. Detect
  • 5.28. Diagenode Diagnostics (Hologic)
  • 5.29. Diasorin S.p.A.
  • 5.30. DNAe
  • 5.31. Domus Diagnostics
  • 5.32. Enzo Biochem
  • 5.33. Eurofins Scientific
  • 5.34. Fluxergy
  • 5.35. Fusion Genomics.
  • 5.36. Genedrive
  • 5.37. Genetic Signatures
  • 5.38. GenMark Dx (Roche)
  • 5.39. Genomadix
  • 5.40. Getlabs
  • 5.41. Global Access Diagnostics
  • 5.42. Grip Molecular Technologies
  • 5.43. Hologic
  • 5.44. Immunexpress
  • 5.45. Inflammatix
  • 5.46. Invetech
  • 5.47. Iollo
  • 5.48. J&J Innovative Medicine
  • 5.49. Karius
  • 5.50. Lucira Health (Pfizer)
  • 5.51. LumiraDx
  • 5.52. Maxim Biomedical
  • 5.53. Meep
  • 5.54. Meridian Bioscience
  • 5.55. Millipore Sigma
  • 5.56. Molbio Diagnostics
  • 5.57. NanoDx
  • 5.58. Nanomix
  • 5.59. Novacyt
  • 5.60. Novel Microdevices
  • 5.61. Novus Diagnostics
  • 5.62. Nuclein
  • 5.63. OnsiteGene
  • 5.64. Operon
  • 5.65. OraSure Technologies
  • 5.66. Oxford Nanopore Technologies
  • 5.67. Panagene
  • 5.68. Prenetics
  • 5.69. Primerdesign (Novacyt)
  • 5.70. Prominex
  • 5.71. Proof Diagnostics
  • 5.72. Qiagen
  • 5.73. QuantuMDx
  • 5.74. QuidelOrtho
  • 5.75. R-Biopharm AG
  • 5.76. Response Biomedical
  • 5.77. Revvity
  • 5.78. Roche Diagnostics
  • 5.79. Salignostics
  • 5.80. SD Biosensor
  • 5.81. Seegene
  • 5.82. Siemens Healthineers
  • 5.83. Sona Nanotech
  • 5.84. SpeeDx
  • 5.85. T2 Biosystems
  • 5.86. Talis Biomedical
  • 5.87. Thermo Fisher Scientific
  • 5.88. Uniogen
  • 5.89. Veramarx
  • 5.90. Veredus Laboratories
  • 5.91. XCR Diagnostics
  • 5.92. Zhejiang Orient Gene Biotech

6. Market Trends

  • 6.1. Factors Driving Growth
    • 6.1.1. New Genotypes Creating New Markets
    • 6.1.2. Aging Population a Boon for All Diagnostics
    • 6.1.3. Developing World Driving ID Dx Growth
    • 6.1.4. Point of Care - Why Centralization is Losing Steam
    • 6.1.5. Self Testing
    • 6.1.6. The Need for Speed
  • 6.2. Factors Limiting Growth
    • 6.2.1. Lower Costs
    • 6.2.2. Infectious Disease is Declining
    • 6.2.3. Wellness Hurts
    • 6.2.4. Economic Growth improves Living Standards

7. Molecular Dx - Infectious Disease Recent Developments

  • 7.1. Recent Developments - Importance and How to Use This Section
    • 7.1.1. Importance of These Developments
    • 7.1.2. How to Use This Section
  • 7.2. Roche to Acquire LumiraDx Point-of-Care Testing Tech
  • 7.3. DiaSorin to Deliver Updated Instruments, New Assays in 2024/25
  • 7.4. ReadyGo Diagnostics, Gemina Labs Expand MDx Pact
  • 7.5. DiagMetrics Developing Breath Assays
  • 7.6. Fortis Life Sciences Acquires IPOC
  • 7.7. Domus Diagnostics Wins NIH RADx Tech Contract
  • 7.8. Llusern Scientific to Launch POC MDx UTI Panel
  • 7.9. Altratech Enters POC MDx Testing Space with Unique Tech
  • 7.10. BioMerieux SpotFire MDx POC System Leverages Novel Approach
  • 7.11. Katalyst Labs to Distribute ProtonDx Dragonfly Rapid IVD System
  • 7.12. LEX Diagnostics Developing Ultra-Fast Low-Cost PCR
  • 7.13. Sherlock Biosciences Adds to Infectious Disease Dx Toolkit
  • 7.14. NanoDx Prepares for Point-of-Care Commercialization
  • 7.15. Paragraf to Study New POC Test to Guide Antibiotic Selection
  • 7.16. MicroGEM to Expand 30-Minute RT-PCR System
  • 7.17. Startup Detect to Roll Out Next-Gen Molecular Instrument
  • 7.18. Diagnostics for the Real World Third-Generation POC Platform
  • 7.19. Salignostics Closes Funding Round
  • 7.20. Cue Health Targets DTC Market in 2022
  • 7.21. Grip Molecular Developing Home Respiratory Panel
  • 7.22. Mainz Biomed Developing Home ColoAlert Assay
  • 7.23. MFB Fertility Closes Series A Financing Round
  • 7.24. Home Test Company Prenetics to go Public
  • 7.25. Roche to Acquire TIB Molbiol to Expand Infectious Disease Portfolio
  • 7.26. BforCure Preparing Multiple Panels for Point-of-Care qPCR Platform
  • 7.27. Talis Biomedical Discusses Point-of-Care
  • 7.28. Roche to Acquire GenMark Diagnostics for $1.8B
  • 7.29. Pandemic Pushes Handheld qPCR Devices Closer to Commercialization
  • 7.30. Hologic to Acquire Mobidiag
  • 7.31. Lucira Health Focuses on User Friendly Approach to Home Testing
  • 7.32. Infectious Disease Dx Firm Talis Biomedical Raises $254M in IPO
  • 7.33. Fluidigm Plans 'Durable' Diagnostics, Clinical Business
  • 7.34. Thermo Fisher Scientific to Acquire Mesa Biotech for Up to $550M
  • 7.35. Mammoth Biosciences Developing Pathogen Detection Tech
  • 7.36. Illumina, IDbyDNA Developing Sequencing-Based Respiratory Tests
  • 7.37. Scanogen Developing 90 Minute Infection Test
  • 7.38. Malaria Assays Use CRISPR for Point-of-Care Multispecies Detection
  • 7.39. FDA Provides Self Testing SARS-CoV-2 EAU Guidance
  • 7.40. Mammoth Biosciences Announces Rapid, CRISPR-Based COVID-19 Diagnostic
  • 7.41. Genetic Signatures Gets CE Mark for Coronavirus Molecular Test
  • 7.42. Qiagen Respiratory Panel with Coronavirus Receives CE Mark
  • 7.43. Lumos Diagnostics Closes $15M Series A Funding

8. The Global Market for Molecular Diagnostics at the Point of Care

  • 8.1. Global Market Overview by Country
    • 8.1.1. Table - Global Market by Country
    • 8.1.2. Chart - Global Market by Country
  • 8.2. Global Market by Application - Overview
    • 8.2.1. Table - Global Market by Application
    • 8.2.2. Chart - Global Market by Application - Base/Final Year Comparison
    • 8.2.3. Chart - Global Market by Application - Base Year
    • 8.2.4. Chart - Global Market by Application - End Year
    • 8.2.5. Chart - Global Market by Application - Share by Year
    • 8.2.6. Chart - Global Market by Application - Segments Growth
  • 8.3. Global Market by Technology - Overview
    • 8.3.1. Table - Global Market by Technology
    • 8.3.2. Chart - Global Market by Technology - Base/Final Year Comparison
    • 8.3.3. Chart - Global Market by Technology - Base Year
    • 8.3.4. Chart - Global Market by Technology - End Year
    • 8.3.5. Chart - Global Market by Technology - Share by Year
    • 8.3.6. Chart - Global Market by Technology - Segments Growth
  • 8.4. Global Market by Place - Overview
    • 8.4.1. Table - Global Market by Place
    • 8.4.2. Chart - Global Market by Place - Base/Final Year Comparison
    • 8.4.3. Chart - Global Market by Place - Base Year
    • 8.4.4. Chart - Global Market by Place - End Year
    • 8.4.5. Chart - Global Market by Place - Share by Year
    • 8.4.6. Chart - Global Market by Place - Segments Growth
  • 8.5. Global Market by Product - Overview
    • 8.5.1. Table - Global Market by Product
    • 8.5.2. Chart - Global Market by Product - Base/Final Year Comparison
    • 8.5.3. Chart - Global Market by Product - Base Year
    • 8.5.4. Chart - Global Market by Product - End Year
    • 8.5.5. Chart - Global Market by Product - Share by Year
    • 8.5.6. Chart - Global Market by Product - Segments Growth

9. Global MDx at the Point of Care Markets - By Application

  • 9.1. Respiratory Infectious Disease
    • 9.1.1. Table Respiratory Infectious Disease - by Country
    • 9.1.2. Chart - Respiratory Infectious Disease Growth
  • 9.2. Gastrointestinal Infectious Disease
    • 9.2.1. Table Gastrointestinal Infectious Disease - by Country
    • 9.2.2. Chart - Gastrointestinal Infectious Disease Growth
  • 9.3. Sexually Transmitted Disease
    • 9.3.1. Table Sexually Transmitted Disease - by Country
    • 9.3.2. Chart - Sexually Transmitted Disease Growth
  • 9.4. Other Application
    • 9.4.1. Table Other Application - by Country
    • 9.4.2. Chart - Other Application Growth

10. Global MDx Markets at the Point of Care - by Technology

  • 10.1. PCR
    • 10.1.1. Table PCR - by Country
    • 10.1.2. Chart - PCR Growth
  • 10.2. NGS/Probe
    • 10.2.1. Table NGS/Probe - by Country
    • 10.2.2. Chart - NGS/Probe Growth
  • 10.3. Other Technology
    • 10.3.1. Table Other Technology - by Country
    • 10.3.2. Chart - Other Technology Growth

11. Global MDx at the Point of Care Markets - by Place

  • 11.1. Hospital Point of Care
    • 11.1.1. Table Hospital Point of Care - by Country
    • 11.1.2. Chart - Hospital Point of Care Growth
  • 11.2. Clinic or Physician Office Lab
    • 11.2.1. Table Clinic or Physician Office Lab - by Country
    • 11.2.2. Chart - Clinic or Physician Office Lab Growth
  • 11.3. Seniors Facility
    • 11.3.1. Table Seniors Facility - by Country
    • 11.3.2. Chart - Seniors Facility Growth
  • 11.4. Other Place
    • 11.4.1. Table Other Place- by Country
    • 11.4.2. Chart - Other Place Growth

12. Global MDx at the Point of Care Markets - by Product

  • 12.1. Instrument
    • 12.1.1. Table Instrument - by Country
    • 12.1.2. Chart - Instrument Growth
  • 12.2. Cartridge
    • 12.2.1. Table Cartridge - by Country
    • 12.2.2. Chart - Cartridge Growth
  • 12.3. Other Product
    • 12.3.1. Table Other Product - by Country
    • 12.3.2. Chart - Other Product Growth

13. Appendices

  • 13.1. Growth of Approved IVD Test Menu
  • 13.2. Growth of Approved Average IVD Test Fee
  • 13.3. The Most Used IVD Assays
  • 13.4. The Highest Grossing Assays
  • 13.5. Laboratory Fees Schedule
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제